Uyku, melatonin ve kanser ilişkisi

Year 2018, Volume: 3 Issue: 1-2, 38 - 41, 04.04.2019

Ali Çimen Yasemin Akbaş Oytun Erbaş

Abstract

Pineal bezinden salgılanan melatoninin sentezi primer olarak karanlığa bağlıdır. Uyku sırasında yapay ışığa maruz kalmak, pineal fonksiyonları akut olarak baskıladığından melatoninin salgılanmasını bozar. Bu bozukluk birçok patolojik duruma ek olarak hormon bağımlı kanserlerden olan meme ve prostat kanseri riskini de artırabilir. Melatonin, antioksidan ve hücre siklusunu yavaşlatıcı özellikleri sayesinde kemoterapi ajanının etkinliğini artırır. Bu nedenle melatonin, hem tek başına hem de diğer tedavilerle birlikte meme ve prostat kanseri için güvenli ve etkili bir tedavi olarak kullanılabilir.

Keywords

Kanser, sirkadiyen ritim, melatonin, pineal bez, uykusuzluk

References

• 1. ener G. Karanlı¤ın hormonu: Melatonin. Marmara Ecza Derg 2010;14:112-20. 2. Owens RL, Gold KA, Gozal D, Peppard PE, Jun JC, Dannenberg AJ, et al. Sleep and Breathing … and Cancer? Cancer Prev Res (Phila) 2016;9:821-7. 3. Lerner AB, Case JD, Takahashi Y, Lee TH, Mori W. Isolation of melatonin, the pineal gland factor that lightens melanocytes. J Amer Chem Soc 1958;80:2587. 4. Reiter RJ, Melchiorri D, Sewerynek E, Poeggeler B, Barlow-Walden L, Chuang J, et al. A review of the evidence supporting melatonin's role as an antioxidant. J Pineal Res 1995;18:1-11. 5. Konturek SJ, Konturek PC, Brzozowska I, Pawlik M, Sliwowski Z, Czesnikiewicz-Guzik M, et al. Localization and biological activities of melatonin in intact and diseased gastrointestinal tract (GIT). J Physiol Pharmacol 2007;58:381-405. 6. Reiter RJ, Carneiro RC, Oh CS. Melatonin in relation to cellular antioxidative defense mechanisms. Horm Metab Res 1997;29:363-72. 7. Arendt J, Skene DJ. Melatonin as a chronobiotic. Sleep Med Rev 2005;9:25-39. 8. Schulz P, Steimer T. Neurobiology of circadian systems. CNS Drugs 2009;23:3-13. 9. Liebmann PM, Wölfler A, Felsner P, Hofer D, Schauenstein K. Melatonin and the immune system. Int Arch Allergy Immunol 1997;112:203-11. 10. Reiter RJ. Melatonin: clinical relevance. Best Pract Res Clin Endocrinol Metab 2003;17:273-85. 11. Jung B, Ahmad N. Melatonin in cancer management: progress and promise. Cancer Res 2006;66:9789-93. 12. Reiter RJ, Tan DX, Korkmaz A, Erren TC, Piekarski C, Tamura H, et al. Light at night, chronodisruption, melatonin suppression, and cancer risk: a review. Crit Rev Oncog 2007;13:303-28. 13. Menéndez-Menéndez J, Martínez-Campa C. Melatonin: An Anti-Tumor Agent in Hormone-Dependent Cancers. Int J Endocrinol 2018;2018:3271948. 14. Sigurdson AJ, Ron E. Cosmic radiation exposure and cancer risk among flight crew. Cancer Invest 2004;22:743-61. 15. Filipski E, Delaunay F, King VM, Wu MW, Claustrat B, Gréchez-Cassiau A, et al. Effects of chronic jet lag on tumor progression in mice. Cancer Res 2004;64:7879-85. 16. Bartsch C, Bartsch H. The anti-tumor activity of pineal melatonin and cancer enhancing life styles in industrialized societies. Cancer Causes Control 2006;17:559-71. 17. Hansen J. Risk of breast cancer after night- and shift work: current evidence and ongoing studies in Denmark. Cancer Causes Control 2006;17:531-7. 18. Figueiro MG, Rea MS, Bullough JD. Does architectural lighting contribute to breast cancer? J Carcinog 2006;5:20. 19. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007;8:286-98. 20. Irmak MK, Topal T, Oter S. Melatonin seems to be a mediator that transfers the environmental stimuli to oocytes for inheritance of adaptive changes through epigenetic inheritance system. Med Hypotheses 2005;64:1138-43. 21. Sharma R, Ottenhof T, Rzeczkowska PA, Niles LP. Epigenetic targets for melatonin: induction of histone H3 hyperacetylation and gene expression in C17.2 neural stem cells. J Pineal Res 2008;45:277-84. 22. Witt-Enderby PA, Radio NM, Doctor JS, Davis VL. Therapeutic treatments potentially mediated by melatonin receptors: potential clinical uses in the prevention of osteoporosis, cancer and as an adjuvant therapy. J Pineal Res 2006;41:297-305. 23. Lissoni P, Barni S, Mandalà M, Ardizzoia A, Paolorossi F, Vaghi M, et al. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Cancer 1999;35:1688-92. 24. Lissoni P, Barni S, Meregalli S, Fossati V, Cazzaniga M, Esposti D, et al. Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. Br J Cancer 1995;71:854-6. 25. Lissoni P, Ardizzoia A, Barni S, Paolorossi F, Tancini G, Meregalli S, et al. A randomized study of tamoxifen alone versus tamoxifen plus melatonin in estrogen receptor-negative heavily pretreated metastatic breast-cancer patients. Oncol Rep 1995;2:871-3. 26. Davis S, Mirick DK, Stevens RG. Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst 2001;93:1557-62. 27. Shah PN, Mhatre MC, Kothari LS. Effect of melatonin on mammary carcinogenesis in intact and pinealectomized rats in varying photoperiods. Cancer Res 1984;44:3403-7. 28. Reiter RJ. Mechanisms of cancer inhibition by melatonin. J Pineal Res 2004;37:213-4. 29. Reiter RJ, Gultekin F, Flores LJ, Terron MP, Tan DX. Melatonin: Toplum sa¤lı¤ını gelitirmek için potansiyel kullanımı. TSK Koruyucu Hekimlik Bülteni 2006;5:131-58.